 Megha Sharma
Concepts (97)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypertension, Pulmonary | 3 | 2022 | 121 | 1.880 |
Why?
| | Infant, Premature | 4 | 2024 | 314 | 1.330 |
Why?
| | Bronchopulmonary Dysplasia | 2 | 2024 | 70 | 1.040 |
Why?
| | Infant, Newborn | 12 | 2024 | 2725 | 0.970 |
Why?
| | Iatrogenic Disease | 1 | 2024 | 24 | 0.950 |
Why?
| | Skin Pigmentation | 1 | 2024 | 11 | 0.910 |
Why?
| | Tracheobronchomalacia | 1 | 2023 | 9 | 0.890 |
Why?
| | Oximetry | 1 | 2024 | 65 | 0.870 |
Why?
| | Persistent Fetal Circulation Syndrome | 1 | 2022 | 9 | 0.800 |
Why?
| | Guanosine Monophosphate | 1 | 2021 | 3 | 0.790 |
Why?
| | Cyclic GMP-Dependent Protein Kinases | 1 | 2021 | 3 | 0.790 |
Why?
| | Neovascularization, Pathologic | 1 | 2021 | 158 | 0.720 |
Why?
| | Exophthalmos | 1 | 2019 | 10 | 0.650 |
Why?
| | Port-Wine Stain | 1 | 2019 | 14 | 0.650 |
Why?
| | Craniosynostoses | 1 | 2019 | 35 | 0.620 |
Why?
| | Intellectual Disability | 1 | 2019 | 125 | 0.580 |
Why?
| | Information Dissemination | 1 | 2016 | 79 | 0.520 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 406 | 0.480 |
Why?
| | Social Media | 1 | 2016 | 98 | 0.480 |
Why?
| | Signal Transduction | 2 | 2021 | 1605 | 0.460 |
Why?
| | Oxidative Stress | 1 | 2017 | 760 | 0.410 |
Why?
| | Pandemics | 1 | 2016 | 566 | 0.390 |
Why?
| | Infant, Very Low Birth Weight | 2 | 2024 | 48 | 0.370 |
Why?
| | Infant | 4 | 2024 | 3565 | 0.360 |
Why?
| | Humans | 15 | 2024 | 49863 | 0.310 |
Why?
| | Animals, Newborn | 2 | 2021 | 365 | 0.310 |
Why?
| | Endothelial Cells | 2 | 2021 | 260 | 0.290 |
Why?
| | Mitochondria | 2 | 2021 | 394 | 0.260 |
Why?
| | Anemia, Neonatal | 1 | 2024 | 5 | 0.240 |
Why?
| | Bradycardia | 1 | 2024 | 36 | 0.230 |
Why?
| | Acidosis | 1 | 2024 | 36 | 0.230 |
Why?
| | High-Frequency Ventilation | 1 | 2024 | 24 | 0.230 |
Why?
| | Ductus Arteriosus, Patent | 1 | 2024 | 38 | 0.230 |
Why?
| | Blood Transfusion | 1 | 2024 | 125 | 0.220 |
Why?
| | Cardiac Catheterization | 1 | 2024 | 213 | 0.200 |
Why?
| | Sheep | 1 | 2021 | 89 | 0.190 |
Why?
| | Administration, Inhalation | 1 | 2022 | 110 | 0.190 |
Why?
| | Vasodilator Agents | 1 | 2022 | 98 | 0.190 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2021 | 78 | 0.190 |
Why?
| | Gastroschisis | 1 | 2021 | 38 | 0.190 |
Why?
| | Female | 6 | 2024 | 26520 | 0.180 |
Why?
| | Healthcare Disparities | 1 | 2024 | 277 | 0.180 |
Why?
| | Pulmonary Artery | 1 | 2021 | 145 | 0.180 |
Why?
| | Nitric Oxide | 1 | 2022 | 254 | 0.170 |
Why?
| | Forehead | 1 | 2019 | 8 | 0.160 |
Why?
| | Hand | 1 | 2019 | 50 | 0.160 |
Why?
| | Fatal Outcome | 1 | 2019 | 194 | 0.160 |
Why?
| | Child, Preschool | 2 | 2024 | 3872 | 0.150 |
Why?
| | Tomography, X-Ray Computed | 1 | 2023 | 1152 | 0.150 |
Why?
| | Lung | 1 | 2022 | 499 | 0.150 |
Why?
| | Aerococcus | 1 | 2017 | 2 | 0.150 |
Why?
| | Aneurysm, Infected | 1 | 2017 | 14 | 0.150 |
Why?
| | Gram-Positive Bacterial Infections | 1 | 2017 | 27 | 0.150 |
Why?
| | Aortic Aneurysm | 1 | 2017 | 25 | 0.140 |
Why?
| | Aneurysm, False | 1 | 2017 | 43 | 0.140 |
Why?
| | Endocarditis, Bacterial | 1 | 2017 | 44 | 0.140 |
Why?
| | Interleukin-10 | 1 | 2016 | 85 | 0.140 |
Why?
| | Serine Proteinase Inhibitors | 1 | 2016 | 10 | 0.140 |
Why?
| | Disease Models, Animal | 1 | 2021 | 1448 | 0.130 |
Why?
| | Cholesterol, LDL | 1 | 2016 | 36 | 0.130 |
Why?
| | Hypolipidemic Agents | 1 | 2016 | 27 | 0.130 |
Why?
| | Dyslipidemias | 1 | 2016 | 36 | 0.130 |
Why?
| | Animals | 3 | 2021 | 13133 | 0.130 |
Why?
| | Oxidation-Reduction | 1 | 2017 | 319 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1038 | 0.130 |
Why?
| | Interleukin-6 | 1 | 2016 | 265 | 0.130 |
Why?
| | Antioxidants | 1 | 2017 | 237 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2016 | 389 | 0.120 |
Why?
| | Retrospective Studies | 2 | 2024 | 6106 | 0.120 |
Why?
| | Pregnancy | 1 | 2021 | 2469 | 0.120 |
Why?
| | Male | 5 | 2024 | 25439 | 0.110 |
Why?
| | Antibodies, Monoclonal | 1 | 2016 | 459 | 0.100 |
Why?
| | Cardiovascular Diseases | 1 | 2016 | 443 | 0.090 |
Why?
| | Case-Control Studies | 2 | 2024 | 1129 | 0.090 |
Why?
| | Risk Factors | 3 | 2024 | 3597 | 0.070 |
Why?
| | United States | 1 | 2016 | 4870 | 0.060 |
Why?
| | Treatment Outcome | 3 | 2024 | 5165 | 0.060 |
Why?
| | Septal Occluder Device | 1 | 2024 | 30 | 0.060 |
Why?
| | Intensive Care Units, Neonatal | 1 | 2024 | 118 | 0.050 |
Why?
| | Gestational Age | 1 | 2024 | 385 | 0.050 |
Why?
| | Heart Rate | 1 | 2024 | 298 | 0.050 |
Why?
| | Prevalence | 1 | 2024 | 951 | 0.050 |
Why?
| | Educational Status | 1 | 2021 | 222 | 0.040 |
Why?
| | Echocardiography, Doppler, Color | 1 | 2017 | 22 | 0.040 |
Why?
| | Aortography | 1 | 2017 | 35 | 0.040 |
Why?
| | Echocardiography, Transesophageal | 1 | 2017 | 60 | 0.040 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2017 | 78 | 0.030 |
Why?
| | Genetic Association Studies | 1 | 2016 | 115 | 0.030 |
Why?
| | Blood Vessel Prosthesis Implantation | 1 | 2017 | 121 | 0.030 |
Why?
| | Drug Discovery | 1 | 2016 | 83 | 0.030 |
Why?
| | Arkansas | 1 | 2021 | 1982 | 0.030 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2016 | 225 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2016 | 483 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 507 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 743 | 0.020 |
Why?
| | Child | 1 | 2021 | 6838 | 0.020 |
Why?
| | Adult | 1 | 2017 | 13325 | 0.010 |
Why?
|
|
Sharma's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|